In clinical relevance, it has been reported that the pathogenesis of SLE is ameliorated by antibodies to IFNα, and patients with hepatitis or malignancy develop SLE when administered IFNα (20). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.